Heron Therapeutics, Inc. (HRTX)

Market Cap	214.61M
Revenue (ttm)	149.69M
Net Income (ttm)	-931,000
Shares Out	153.29M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,094,396
Open	1.470
Previous Close	1.310
Day's Range	1.315 - 1.470
52-Week Range	1.040 - 2.680
Beta	1.15
Analysts	Strong Buy
Price Target	4.50 (+221.43%)
Earnings Date	Aug 8, 2025

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 122
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX
• Website: https://www.herontx.com

Financial Performance

In 2024, Heron Therapeutics's revenue was $144.29 million, an increase of 13.57% compared to the previous year's $127.04 million. Losses were -$13.58 million, -87.72% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 221.43% from the latest price.

Price Target

$4.5

(221.43% upside)

Analyst Consensus: Strong Buy